In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...

Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading ... You can see the complete ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Apollo Tyres, Thermax, PI Industries, Deepak Nitrite, Bayer CropScience, Brigade Enterprises, NBCC (India), Wockhardt, ...

Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...

This collaboration combines Absci's integrated drug creation platform with Astrazeneca's expertise in oncology ... we are pleased to be adding another new partner to our diverse list of collaborators ...

Greetings and welcome to I US third quarter, 2024 earnings conference call. (Operators Instructions). I would now like to turn the conference over to your host, Jordan Shapiro. Thank you. You may ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...